Search research articles
Contact Us
Filters
Showing results (391-400 of 643) with videos related to
Page
of 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
Vivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
JCO Precision Oncology
|
September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA
Nora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
Molecular Cancer Therapeutics
|
April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterations
Kaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Cold Spring Harbor Molecular Case Studies
|
January 5, 2017
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, et al.
Cancer
|
March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancer
Alexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Oncotargets and Therapy
|
May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Annals of Surgery
|
January 25, 2006
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
Anees B Chagpar, Lavinia P Middleton, Aysegul A Sahin, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Scientific Reports
|
November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Turcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Page
of 65
Search research articles
Search
Showing results (391-400 of 643) with videos related to
Sort By:
Page
of 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
Vivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
JCO Precision Oncology
|
September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA
Nora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
Molecular Cancer Therapeutics
|
April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterations
Kaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Cold Spring Harbor Molecular Case Studies
|
January 5, 2017
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, et al.
Cancer
|
March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancer
Alexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Oncotargets and Therapy
|
May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Annals of Surgery
|
January 25, 2006
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
Anees B Chagpar, Lavinia P Middleton, Aysegul A Sahin, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Scientific Reports
|
November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Turcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Page
of 65